CMS Reimbursement Code
Represented Ferring Pharmaceuticals-USA, which manufactures the first bioengineered, injectable hyaluronic acid approved by the FDA for the treatment of osteoarthritis of the knee, in reclassifying its CMS reimbursement code for the drug so that it would have the same code as its competitors.Service Areas
- Bankruptcy and Creditors' Rights
- Corporate Finance & Technology
- E-Discovery Team
- Energy and Utility Law
- Environmental Law
- ERISA/Employee Benefits
- Family Law and Mediation
- Financial Crisis Team
- Financial Services
- Food and Drug (FDA)
- Government Contracts
- Government Relations - Federal
- Government Relations - State
- Academic Institutions
- Banking and Financial Institutions
- Economic Development
- Energy
- Health Care
- Insurance
- Municipalities, School Districts and Authorities
- Nonprofit/Cultural Organizations
- Pharmaceutical/Biotech
- Public Finance
- Public Private Partnerships
- Technology: Procurement Capabilities
- Trade Associations/Organizations
- Transportation
- Health Care
- Immigration
- Intellectual Property
- Intellectual Property Litigation
- International Services
- Labor and Employment Law
- Acquisition and Divestiture Assistance
- Alternative Dispute Resolution
- Counseling on Human Resource and Employee Relations Issues
- Employment Litigation
- Employment-Related Class and Collective Action Litigation
- Immigration
- Railway Labor Act
- Trade Secrets and Restrictive Covenants
- Traditional Labor Relations
- Wage Payment and Fair Labor Standards Act (Overtime Pay) Matters
- Workers' Compensation
- Workplace Safety and Health (OSHA and MSHA)
- Life Sciences
- Litigation
- Real Estate
- Tax
- Water Law